Search

Your search keyword '"Mohr, Peter"' showing total 459 results

Search Constraints

Start Over You searched for: Author "Mohr, Peter" Remove constraint Author: "Mohr, Peter" Search Limiters Peer Reviewed Remove constraint Search Limiters: Peer Reviewed
459 results on '"Mohr, Peter"'

Search Results

1. Mutation analysis in individual circulating tumor cells depicts intratumor heterogeneity in melanoma

2. Interim analysis of the multinational, post-authorization safety study (NISSO) to assess the long-term safety of sonidegib in patients with locally advanced basal cell carcinoma

4. Early versus late response to PD-1-based immunotherapy in metastatic melanoma

5. Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy – A multicenter study on 2419 patients from the prospective skin cancer registry ADOReg

6. Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial

7. Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial

8. Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (“Triple”) wild type melanomas

9. Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases

11. Real-World efficiency of pembrolizumab in metastatic melanoma patients following adjuvant anti-PD1 treatment

14. Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma – analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM

15. Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial

17. Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study

18. Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG

19. Cross sections at sub-Coulomb energies: full optical model vs.\ barrier transmission for $^{40}$Ca + $\alpha$

20. Characterisation and outcome of RAC1 mutated melanoma

21. 2022 taxonomic update of phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales

22. German S3 guideline “actinic keratosis and cutaneous squamous cell carcinoma” – Long version of the update 2023

23. Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study

24. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial

25. Clinical determinants of long-term survival in metastatic uveal melanoma

26. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial

27. Uncertainty of the astrophysical $^{17,18}$O($\alpha$,n)$^{20,21}$Ne reaction rates and the applicability of the statistical model for nuclei with $A \lesssim 20$

28. Influence of adjuvant therapies on organ‐specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADOReg.

29. Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in Europe.

32. NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors

33. Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma

35. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

36. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

37. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition

38. Total reaction cross section of light stable and exotic nuclei on lead at energies around the Coulomb barrier.

39. Dr Graham Steell and monaural stethoscopes: Cardiology before the ECG.

40. BRAFV600E Metastatic Melanoma Journey: A Perspective from a Patient and his Oncologist.

43. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial

45. Constraining nucleosythesis in neutrino-driven winds using the impact of (α, xn) reaction rates

48. Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events.

49. Telefonische Verlaufskontrolle nach ambulanten nagelchirurgischen Eingriffen – eine retrospektive Analyse.

50. Telephone follow‐up after outpatient nail surgery – a retrospective analysis.

Catalog

Books, media, physical & digital resources